Cellectis S.A. - American Depositary Shares (CLLS)

Competitors to Cellectis S.A. - American Depositary Shares (CLLS)

Bluebird Bio, Inc. 

Bluebird Bio specializes in gene therapy and gene editing technologies aimed at treating genetic diseases and cancer, like Cellectis. While Cellectis focuses primarily on TALEN technology and T-cell therapy, Bluebird Bio differentiates itself with its focus on integration and high-throughput gene therapies, which positions them uniquely in the competitive landscape, though this may not necessarily indicate a leading advantage.

CRISPR Therapeutics AG 

CRISPR Therapeutics AG focuses on CRISPR/Cas9 gene-editing technology, similar to Cellectis' work in gene editing and cell therapy. Both companies are engaged in developing therapies for genetic diseases and cancer, resulting in competition for funding, talent, and market share. CRISPR's collaboration with Vertex Pharmaceuticals for gene-editing therapies gives it significant resources and visibility, allowing them to rapidly advance their pipeline.

Editas Medicine, Inc. 

Editas Medicine, Inc. is a key player in the gene editing sector through the application of CRISPR technology, which places it in direct competition with Cellectis. Both companies are developing gene therapies and treatments for various genetic disorders, but Editas has a strong focus on ocular therapies and has made significant advancements in clinical trials, giving it a competitive edge in specific therapeutic areas.

Intellia Therapeutics, Inc. 

Intellia Therapeutics focuses on using CRISPR/Cas9 technology for in vivo gene editing therapies, positioning it as a direct competitor to Cellectis. Intellia has made considerable progress in its clinical programs and demonstrates a robust pipeline that may give it a competitive advantage, especially with their focus on single-dose genetic therapies, whereas Cellectis emphasizes engineered CEA T cells.

Novartis AG 

Novartis AG, a major player in the pharmaceutical sector, has invested in CAR-T cell therapies and gene editing initiatives that overlap with Cellectis' focus on engineered T-cell therapies. The company's established pipeline, financial resources, and broad market presence offer Novartis a competitive advantage over smaller firms such as Cellectis, allowing them to attract talent and partnerships more easily.